Medication info
Qurorica Capsule 75 mg (Pregabalin)

Qurorica Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Dasan Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a brownish upper part and a white lower part filled with white powder.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201801697 · Approved 2018.04.20 · Insurance code 678600870

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this drug is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, depending on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* *For women, multiply the result obtained using the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ / Dosage regimen ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment Dose adjustment is not required in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Dasan Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for patients with epilepsy experiencing partial seizures. Furthermore, it is effective in the treatment of fibromyalgia, which includes the treatment of neuropathic pain, epilepsy, and fibromyalgia.

How to take

Adult dose

This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this drug is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, depending on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* *For women, multiply the result obtained using the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ / Dosage regimen ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment Dose adjustment is not required in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if there are any mood changes or abnormal behaviors during treatment, it should be reported to healthcare providers immediately. Pregabalin or any component of this medication should not be taken if there is an allergy. Patients with certain genetic disorders such as lactose intolerance should also avoid this medication. Diabetic patients may need to adjust their doses of blood sugar control medicines due to weight gain. If symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients should be cautious due to the risk of injury from dizziness or drowsiness and may experience vision changes such as blurred vision. Sudden discontinuation of this medication may result in withdrawal symptoms such as insomnia, headaches, and anxiety, thus dosage adjustments should be discussed with a healthcare provider. Patients with a history of substance abuse are at a higher risk of misuse of this medication and should use it cautiously. Dose adjustments may be necessary for patients with impaired kidney function. Patients with heart disease should also use this medication cautiously. Caution should be taken when used with opioid analgesics as there is a risk of central nervous system depression. Pregnant women or those planning to become pregnant should consult with a healthcare provider as it may affect the fetus. Nursing mothers should consider discontinuing breast-feeding or stopping the medication as it may be transmitted through breast milk. It is advisable to avoid operating vehicles or machinery until dizziness or drowsiness has resolved after taking this medication. Serious skin reactions may occur; if a rash or swelling appears, discontinue the medication and inform a healthcare provider immediately. Overdose may lead to confusion, drowsiness, depression, and seizures, requiring immediate emergency treatment. Keep out of reach of children and do not transfer to another container.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 174 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • diminished oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • hives
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast hypertrophy
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feelings of intoxication
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • sense of well-being
  • decreased libido
  • depersonalization
  • paraphilia
  • restlessness
  • mood swings
  • emotional low
  • emotional highs
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • flat affect
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory impairment
  • tremors
  • dysarthria
  • altered sensation
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • sensory hypersensitivity
  • burning sensation
  • tremors during activity
  • syncope
  • confusion
  • motor retardation
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • homogenous bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tightness
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusion
  • depression
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 15 degrees and 30 degrees Celsius. This will help preserve the effectiveness and safety of the medication for a longer period.

Appearance and packaging

Appearance

A hard capsule with a brownish upper part and a white lower part filled with white powder.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.